- Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., Ltd
- AnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices
- AnPac Bio’s board now includes Mr. Chao Feng who has global fortune 500 Companies’ managerial experience as independent director effective July 19, 2021
AnPac Bio-Medical Science (NASDAQ: ANPC), an innovative thought leader and biotechnology company focused on early screening and cancer detection by developing, distributing, and deploying accessible early disease detection devices, announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holding AG, to explore novel healthcare and medical solutions. The collaboration will leverage both parties’ advantages and resources to work on early cancer screening, diagnosis, and treatment (https://ibn.fm/4PpPO).
AnPac Bio is an early thought leader and innovator in the field of cancer screening, where it has already made notable contributions including as an early thought leader and technology leader of multi-(pan) cancer screening and multi-level and multi-parameter innovation and screening products. By 2014, AnPac Bio announced that the cancer detection technology it developed was capable of screening 16 types of cancer, and was one of the earliest companies to begin marketing a pan-cancer screening and detection test in 2015, when it began commercial operations.
Per the agreement signed by AnPac Bio and Roche, both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (“CDA”) cancer detection technology and Roche’s FoundationOne CDx to create a solution that customers with a high cancer risk level as assessed by CDA and later diagnosed with cancer can receive a personalized CDx precision medical test for therapy selection. The parties aim to help benefit the general population while lowering costs and saving patient lives.
Th cancer screening and diagnostic market is expanding, with the number of cancer cases reported worldwide also growing. According to the World Health Organization (“WHO”), there were 135 million cancer patients globally in 2020, with 32 million geographically located in China. The new figures mark a 20 million increase in the number of worldwide cases, 4.7 million of which in China.
The cooperation agreement with Roche comes after AnPac Bio’s agreement with Advanced Life Therapeutics Co., Ltd. The company holds minority equity of 40% in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices (https://ibn.fm/RIHTd). The partnership with Advanced Life Therapeutics is a multi-year contract to design, fabricate, test, and optimize key components of a cancer treatment medical device. AnPac Bio expects to begin generating revenue from this contract R&D project starting Q3 of this year.
AnPac Bio is in the later stages of cooperation and partnership discussions with multiple major corporations in the medical industry aimed at increasing commercial CDA-based cancer test revenue and broadening a new product pipeline for itself and its partners. The agreements with Advanced Life Therapeutics and Roche announced recently.
Effective July 19, 2021, Mr. Chao Feng was named as her successor to take the role of independent director immediately (https://ibn.fm/IDUPZ), with Ms. Lin Yu resigned as the director of AnPac Bio. Having previously worked for two global Fortune 500 companies in China, Mr. Chao Feng served as general manager for Shanghai Zhiruihaochen Information Technology Co., Ltd. since 2019. Additionally, he has been the chairman of the strategy committee of Guangzhou Chengding Robots Co., Ltd. since 2016.
In his role as the new independent director of AnPac Bio, Mr. Feng said, “AnPac Bio has been recognized in the field of early cancer screening and detection, and I’m excited to be a part of the team. I look forward to contributing to AnPac Bio’s future success as a member of its Board and helping the Company in its further development.”
Dr. Chris Yu, CEO and Chairman of the Board for AnPac Bio, welcomed Mr. Feng to the team, praising his experience. “His strong academic background and business management experience, particularly in strategic planning, capital market transactions, and sales, will benefit our Company in our pursuit of long-term growth,” Dr. Yu said.
Through its CDA technology, AnPac Bio aims to tackle multiple aspects and challenges of the cancer screening and diagnostics industry. Using the natural biophysical properties of blood and cellular proteins to discover cancerous environments within the body before the tumors form and being powered by a database of over 200,000 samples and cases, CDA has been able to diagnose and identify pre- and early-stage cancers in patients that were previously diagnosed as cancer-free through traditional methods.
For more information, visit the company’s website at www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.